Skip to content
Head to head

AbCellera Biologics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: ABCL · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

ABCL +169.2%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
ABCLVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price9.69515.02
Change today-7.45%-1.08%
1-year return+184.2%+22.0%
Market cap$3.16B$130.58B
52-week range2.75 – 15.02412.27 – 568.67
Valuation
P/E (TTM)-20.1933.14
P/E percentile, own 5-yr range6th99th
P/B2.986.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.4915.32
Net profit (TTM)$-160.04M$3.88B
Revenue (TTM)$67.86M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+18.8%+11.8%
Gross margin100.0%85.5%
Operating margin-275.7%33.1%
Net margin-218.6%30.7%
Free cash flow (TTM)$-32.85M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership37.2%96.8%
Insider activity (12mo)45 buy / 4 sell28 buy / 22 sell
Short interest (% of float)9.0%1.9%
Analyst consensus89% buy / 11% hold (9)95% buy / 5% hold (21)
Analyst price target$19 (+99%)$624 (+21%)
StockVane view
StockVane Quant RatingC (99)C (68)
Company
Employees5626,400
Founded20121989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.